Home/Filings/4/0001104659-23-126916
4//SEC Filing

O'Neill Vincent 4

Accession 0001104659-23-126916

CIK 0001720893other

Filed

Dec 17, 7:00 PM ET

Accepted

Dec 18, 4:47 PM ET

Size

7.3 KB

Accession

0001104659-23-126916

Insider Transaction Report

Form 4
Period: 2023-12-14
Transactions
  • Exercise/Conversion

    Common Stock

    2023-12-14+5212,802 total
  • Exercise/Conversion

    Restricted Stock Units

    2023-12-145214,690 total
    Common Stock (521 underlying)
Footnotes (2)
  • [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
  • [F2]On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.

Issuer

BioXcel Therapeutics, Inc.

CIK 0001720893

Entity typeother

Related Parties

1
  • filerCIK 0001672718

Filing Metadata

Form type
4
Filed
Dec 17, 7:00 PM ET
Accepted
Dec 18, 4:47 PM ET
Size
7.3 KB